Overview

STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)

Status:
Completed
Trial end date:
2016-12-12
Target enrollment:
Participant gender:
Summary
This study evaluated bradycardiac events during first dose observation of fingolimod in MS patients.
Phase:
Phase 4
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
Fingolimod Hydrochloride